Pamicell Expects Increase in Active Pharmaceutical Ingredients... 'RNA Therapeutics Development to Follow'

[Asia Economy Reporter Hyungsoo Park] Global pharmaceutical company Novartis's hyperlipidemia treatment 'Inclisiran' received FDA approval in the United States on the 22nd local time, and it is expected that the raw material pharmaceutical sales of the domestic bio company Pharmicell will increase.

Inclisiran is the first RNA-based treatment in the chronic disease field and is a hyperlipidemia treatment based on siRNA. Unlike existing competing products that require dozens of doses annually, it attracts industry attention by achieving the same therapeutic effect with only two doses per year. It is expected to achieve annual sales of over $2 billion by 2026.

Inclisiran has received product approval in Europe, the United Kingdom, and now the United States, and the demand for raw materials is also expected to increase. Related industries anticipate sales growth for Pharmicell, as DMT-2’-OME-RNAs, a type of nucleoside produced by Pharmicell, are used in more than 70% of Inclisiran manufacturing, leading to increased nucleoside demand.

Pharmicell consecutively secured orders for nucleosides worth 9 billion KRW in September and 10.2 billion KRW in December this year. Nucleoside sales recorded 13.5 billion KRW, a 20% increase compared to the third quarter of last year.

RNA therapeutics were initially developed for rare diseases such as genetic disorders but have recently expanded their pipeline to chronic diseases, with about 500 new drug development investments currently ongoing. Research firm Research and Market forecasts that the RNA-based therapeutics market will grow to approximately $8.2 billion by 2030.